Ximelagatran: An eulogy

被引：28

作者：

Boos, Christopher J. ^{[1
]}

Lip, Gregory Y. H. ^{[1
]}

机构：

[1] Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England

来源：

THROMBOSIS RESEARCH | 2006年 / 118卷 / 03期

关键词：

D O I：

10.1016/j.thromres.2006.02.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：301 / 304

页数：4

共 22 条

[1]

Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690

[2]

Albers GW, 2003, LANCET, V362, P1691

[3] The pharmacology and management of the vitamin K antagonists [J].

Ansell, J ;

Hirsh, J ;

Poller, L ;

Bussey, H ;

Jacobson, A ;

Hylek, E .

CHEST, 2004, 126 (03) :204S-233S

[4]

Boos Christopher J, 2005, Expert Rev Cardiovasc Ther, V3, P551, DOI 10.1586/14779072.3.4.551

[5] How good is anticoagulation control in non-valvar atrial fibrillation? Observations on the elderly, ethnicity, patient perceptions, and understanding of AF thromboprophylaxis [J].

Choudhury, A ;

Lip, GYH .

HEART, 2005, 91 (04) :425-426

[6] Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction [J].

Christersson, C ;

Oldgren, J ;

Bylock, A ;

Wallentin, L ;

Siegbahn, A .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (10) :2245-2253

[7] Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation - Pooled analysis from the SPORTIF III and V studies [J].

Diener, HC .

CEREBROVASCULAR DISEASES, 2006, 21 (04) :279-293

[8] Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement [J].

Eriksson, BI ;

Borris, L ;

Dahl, OE ;

Haas, S ;

Huisman, MV ;

Kakkar, AK ;

Misselwitz, F ;

Kälebo, P .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (01) :121-128

[9] A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial [J].

Eriksson, BI ;

Dahl, OE ;

Büller, HR ;

Hettiarachchi, R ;

Rosencher, N ;

Bravo, ML ;

Ahnfelt, L ;

Piovella, F ;

Stangier, J ;

Kälebo, P ;

Reilly, P .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :103-111

[10]

*FDA ADV COMM BRIE, 2004, EX XIM TABL

← 1 2 3 →